|Price and Volume|
|52 Week High||17.42|
|52 Week Low||4.95|
|Avg. Daily Vol. (Mil)||1.91|
|Beta (3 year)||2.98|
|Share Related Items|
|Mkt Cap (Mil)||370.67|
|Shares Out (Mil)||54.79|
|LT Debt/ Equity||0.00|
|Total Debt / Equity||0.01|
|Per Share Data|
|Arrowhead Research Corp is engaged in developing novel drugs to treat intractable diseases by silencing the genes. The Company's drug candidate ARC-520 is designed to treat chronic hepatitis B infection.|
|225 South Lake Avenue
Pasedena, CA 91101
|Industry : Drugs|
|Sector: Health Care|
|CEO: Dr. Christopher Anzalone|
|Current Month (Mil)||14.50|
|Previous Month (Mil)||14.51|
|Short Interest Ratio (Days)||8.60|
|Return on Equity||n.a.|
|Return on Assets||-43.60|
|Return on Investments||-48.00|
|Rating||Current||1-Mo Ago||2-Mo Ago||3-Mo Ago|
|GET ARWR ANALYST REPORT|
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.